Frost & Sullivan

OCTOBER 1, 2024

October 1, 2024 – Frost & Sullivan assessed the laboratory information management systems (LIMS) industry and, based on its findings, recognizes LabVantage Solutions with the 2024 Global Company of the Year Award. SAN ANTONIO, TX. LabVantage LIMS is an enterprise platform serving the full product life cycle.

Life science 104

Life science Biotechnology Consumer packaged goods Strategic partnership 104

Jake Jorgovan

AUGUST 13, 2024

They distinguish themselves by focusing on creating not just campaigns but " feel-good moments" that bond brands with their audiences, emphasizing collaboration and innovation. You benefit from their unique blend of digital marketing, advertising, and public relations to significantly enhance your brand's engagement and reach.

Biotech 130

Biotech Retail Life science Finance 130

Frost & Sullivan

AUGUST 29, 2024

growth from 2023 to 2024. Competitive Intensity: Pursuing Cross-Industry Collaborations Forging partnerships between pharmaceutical and technology companies to innovate and streamline drug development processes, creating competitive advantages. However, the pharma/biopharma industry overall shows stagnant R&D activity.

Biopharma 52

Biopharma Biotechnology Contract research organization Utilities 52

LaVoie Health Science Blog

DECEMBER 21, 2023

Looking ahead to 2024, professionals worldwide are eagerly gearing up for one of the most anticipated events in the financial calendar—the J.P. Morgan 2024 experience. Keep an eye on evolving partnership models and consider how your business can leverage these collaborative opportunities. Morgan Healthcare Conference.

Biopharmaceuticals 59

Biopharmaceuticals Biotechnology Life science Biotech 59

Frost & Sullivan

APRIL 3, 2024

The Drug, Chemical & Associated Technologies Association (DCAT) 2024 event held in New York City on March 18-21 showcased product and technology innovations and capabilities presentations by member companies. FUJIFILM Diosynth Biotechnologies invested $1.6 The company’s acquisition of Summit Biosciences Inc.

Biopharmaceuticals 59

Biopharmaceuticals Biopharma Biotechnology Life science 59

Frost & Sullivan

MARCH 28, 2025

The pharmaceutical and biotechnology industries are at the cusp of a transformative era in 2025, driven by cutting-edge innovation, evolving regulations, and increasing market pressures. Leading the charge, Novartis Pluvicto has already surpassed blockbuster sales in 2024, highlighting immense investment potential.

Biotech 52

Biotech Biotechnology Strategic partnership Insurance 52

Frost & Sullivan

MAY 9, 2025

billion in 2024, is projected to grow at a CAGR of 10.7%, reaching $122.13 This article explores the key trends, market drivers, and emerging opportunities in the pharmaceutical clinical contract peripheral services market from 2024 to 2030. The global CRO industry, valued at $66.39 billion by 2030.

Mergers and acquisition activities 52

Mergers and acquisition activities Biopharma Biotechnology Biotech 52